An update from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. announced a managerial transaction involving Bert van Meurs, a member of the administrative body, who was granted 5,990 Restricted Stock Units as part of a share option program. This transaction, not quantifiable in terms of price or volume, took place outside a trading venue on February 28, 2025, and reflects the company’s ongoing commitment to aligning managerial interests with shareholder value.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples, with a market focus on enhancing the capabilities of laboratories and research institutions globally.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.